Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

References

• World Health Organization. Antimicrobial resistance. Geneva, Switzerland: WHO; 2022 [accessed 2022 Dec 15]. https://www.who.int/health-topics/antimicrobial-resistance
   Google Scholar
• World Health Organization. Antimicrobial resistance. Geneva, Switzerland: WHO; 2021 [accessed 2022 Dec 15]. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
   Google Scholar
• Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–5. doi:10.2147/IDR.S234610.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi:10.1016/S0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccines Immunother. 2018;14(9):2142–9. doi:10.1080/21645515.2018.1476814.
   PubMed Web of Science ®Google Scholar
• Atkins KE, Lafferty EI, Deeny SR, Davies NG, Robotham JV, Jit M. Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. Lancet Infect Dis. 2018;18(6):e204–13. doi:10.1016/S1473-3099(17)30478-4.
   PubMed Web of Science ®Google Scholar
• Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021;19(5):287–302. doi:10.1038/s41579-020-00506-3.
   PubMed Web of Science ®Google Scholar
• Buchy P, Ascioglu S, Buisson Y, Datta S, Nissen M, Tambyah PA, Vong S. Impact of vaccines on antimicrobial resistance. Int J Infect Dis. 2020;90:188–96. doi:10.1016/j.ijid.2019.10.005.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA. 2018;115(51):12896–901. doi:10.1073/pnas.1721095115.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Black S, Salisbury D, Rappuoli R. Antimicrobial resistance and the role of vaccines. Proc Natl Acad Sci USA. 2018;115(51):12868–71. doi:10.1073/pnas.1717157115.
   PubMed Web of Science ®Google Scholar
• Sevilla JP, Bloom DE, Cadarette D, Jit M, Lipsitch M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc Natl Acad Sci USA. 2018;115(51):12911–19. doi:10.1073/pnas.1717161115.
   PubMed Web of Science ®Google Scholar
• Standaert B, Rappuoli R. 2. How is the economic assessment of vaccines performed today? J Mark Access Health Policy. 2017;5(1):1335163. doi:10.1080/20016689.2017.1335163.
   PubMedGoogle Scholar
• Annemans L, Beutels P, Bloom DE, De Backer W, Ethgen O, Luyten J, Van Wilder P, Willem L, Simoens S. Economic evaluation of vaccines: Belgian reflections on the need for a broader perspective. Value Health. 2021;24(1):105–11. doi:10.1016/j.jval.2020.09.005.
   PubMed Web of Science ®Google Scholar
• Bell E, Neri M, Steuten L. Towards a broader assessment of value in vaccines: the BRAVE way forward. Appl Health Econ Health Policy. 2022;20(1):105–17. doi:10.1007/s40258-021-00683-z.
   PubMed Web of Science ®Google Scholar
• Lu E, Chen HH, Zhao H, Ozawa S. Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China. Proc Natl Acad Sci. 2021;118(13):e2004933118. doi:10.1073/pnas.2004933118.
   PubMedGoogle Scholar
• Ozawa S, Chen HH, Rao GG, Eguale T, Stringer A. Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): case study using DREAMR in Ethiopia. Vaccine. 2021;39(45):6700–11. doi:10.1016/j.vaccine.2021.04.024.
   PubMed Web of Science ®Google Scholar
• Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, English M, Scott JAG. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLos One. 2013;8(6):e67324. doi:10.1371/journal.pone.0067324.
   PubMed Web of Science ®Google Scholar
• Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health. 2013;13(1):1025. doi:10.1186/1471-2458-13-1025.
   PubMedGoogle Scholar
• Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine. 2015;33:A143–53. doi:10.1016/j.vaccine.2014.12.078.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee G, Goldie SJ. Economic evaluation of pneumococcal conjugate vaccination in the Gambia. BMC Infect Dis. 2010;10(1):260. doi:10.1186/1471-2334-10-260.
   PubMedGoogle Scholar
• Komakhidze T, Hoestlandt C, Dolakidze T, Shakhnazarova M, Chlikadze R, Kopaleishvili N, Goginashvili K, Kherkheulidze M, Clark AD, Blau J. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia. Vaccine. 2015;33:A219–26. doi:10.1016/j.vaccine.2014.12.070.
   PubMed Web of Science ®Google Scholar
• Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, Punpanich W, Teerawattananon Y. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31(26):2839–47. doi:10.1016/j.vaccine.2013.03.047.
   PubMed Web of Science ®Google Scholar
• Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, et al. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015;33:A154–66. doi:10.1016/j.vaccine.2014.12.039.
   PubMed Web of Science ®Google Scholar
• Nakamura MM, Tasslimi A, Lieu TA, Levine O, Knoll MD, Russell LB, Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health. 2011;3(4):270–81. doi:10.1016/j.inhe.2011.08.004.
   PubMed Web of Science ®Google Scholar
• Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, et al. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33:A182–91. doi:10.1016/j.vaccine.2014.12.044.
   PubMed Web of Science ®Google Scholar
• Sundaram N, Chen C, Yoong J, Luvsan ME, Fox K, Sarankhuu A, La Vincente S, Jit M. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. 2017;35(7):1055–63. doi:10.1016/j.vaccine.2016.12.070.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Saha A, Zhang XH. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Eff Resour Alloc. 2017;15(1):17. doi:10.1186/s12962-017-0079-2.
   PubMedGoogle Scholar
• Zhou H, He J, Wu B, Che D. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Hum Vaccines Immunother. 2018;14(6):1444–52. doi:10.1080/21645515.2018.1438794.
   PubMed Web of Science ®Google Scholar
• Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, Kleinman K, Hinrichsen VL, Fraser C. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics. 2010;2(2):80–4. doi:10.1016/j.epidem.2010.03.005.
   PubMed Web of Science ®Google Scholar
• Løchen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10(1):18977. doi:10.1038/s41598-020-75691-5.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet (London, England). 2011;378(9807):1962–73. doi:10.1016/S0140-6736(10)62225-8.
   PubMed Web of Science ®Google Scholar
• Kim SH, Chung DR, Song JH, Baek JY, Thamlikitkul V, Wang H, Carlos C, Ahmad N, Arushothy R, Tan SH, et al. Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes. Vaccine. 2020;38(38):6065–73. doi:10.1016/j.vaccine.2019.09.065.
   PubMed Web of Science ®Google Scholar
• Obolski U, Lourenço J, Thompson C, Thompson R, Gori A, Gupta S. Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae. Proc Natl Acad Sci USA. 2018;115(12):3102–7. doi:10.1073/pnas.1718712115.
   PubMed Web of Science ®Google Scholar
• Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M, Benisty R, Givon-Lavi N, Hawkins PA, Cornick JE, Kwambana-Adams B, et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019;19(7):759–69. doi:10.1016/S1473-3099(19)30297-X.
   PubMed Web of Science ®Google Scholar
• Yahiaoui RY, Bootsma HJ, den Heijer CDJ, Pluister GN, John Paget W, Spreeuwenberg P, Trzcinski K, Stobberingh EE. Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis. 2018;18(1):440. doi:10.1186/s12879-018-3341-0.
   PubMedGoogle Scholar
• Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, Knight GM, Robotham JV. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7(1):58. doi:10.1186/s13756-018-0336-y.
   PubMedGoogle Scholar
• Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7(1):98. doi:10.1186/s13756-018-0384-3.
   PubMedGoogle Scholar
• Jit M, Ng DHL, Luangasanatip N, Sandmann F, Atkins KE, Robotham JV, Pouwels KB. Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Med. 2020;18(1):38. doi:10.1186/s12916-020-1507-2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Bacterial vaccines in clinical and preclinical development: an overview and analysis. Geneva, Switzerland: WHO; 2022 [accessed 2022 Dec 15]. https://www.who.int/publications/i/item/9789240052451
   Google Scholar
• Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: understanding better to address better. Isr J Health Policy Res. 2016;5(1):2. doi:10.1186/s13584-016-0062-y.
   PubMedGoogle Scholar
• World Health Organization. Global action plan on antimicrobial resistance. Geneva, Switzerland: WHO; 2015 [accessed 2022 Dec 15]. https://www.who.int/publications/i/item/9789241509763
   Google Scholar
• Naylor NR, Zhu N, Hulscher M, Holmes A, Ahmad R, Robotham JV. Is antimicrobial stewardship cost-effective? A narrative review of the evidence. Clin Microbiol Infect. 2017;23(11):806–11. doi:10.1016/j.cmi.2017.06.011.
   PubMed Web of Science ®Google Scholar
• Stenberg K, Hanssen O, Edejer T-T, Bertram M, Brindley C, Meshreky A, Rosen JE, Stover J, Verboom P, Sanders R, et al. Financing transformative health systems towards achievement of the health sustainable development goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Glob Health. 2017;5(9):e875–87. doi:10.1016/S2214-109X(17)30263-2.
   PubMed Web of Science ®Google Scholar